AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Gene Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 17966130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity

  2005cited by this paper
• Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer

  2005cited by this paper
• Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.

  2005cited by this paper
• Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma

  2005cited by this paper
• Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus AdΔ24-p53 against Human Malignant Glioma

  2004cited by this paper
• Multicellular tumor spheroids in gene therapy and oncolytic virus therapy.

  2004cited by this paper
• Brain tumours: classification and genes

  2004cited by this paper
• Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy.

  2004cited by this paper
• A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

  2004cited by this paper
• Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

  2003cited by this paper
• Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins.

  2003cited by this paper
• Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.

  2003cited by this paper
• Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein

  2003cited by this paper
• Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.

  2002cited by this paper
• Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.

  2002cited by this paper
• Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency.

  2002cited by this paper
• Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.

  2002cited by this paper
• Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma

  2002cited by this paper
• Late Expression of p53 from a Replicating Adenovirus Improves Tumor Cell Killing and Is More Tumor Cell Specific than Expression of the Adenoviral Death Protein

  2002cited by this paper
• Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.

  2002cited by this paper
• The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro.

  2002cited by this paper
• Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model.

  2002cited by this paper
• Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

  2001cited by this paper
• CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.

  2001cited by this paper
• E1B-Deleted Adenovirus (dl1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors

  2001cited by this paper
• A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

  2001cited by this paper
• Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53.

  2000cited by this paper
• A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

  2000cited by this paper
• In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.

  2000cited by this paper
• Quiescence in S-phase and G 1 arrest induced by irradiation and/or hyperthermia in six human tumour cell lines of different p53 status

  2000cited by this paper
• A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo

  2000cited by this paper
• Combined radiation and p53 gene therapy of malignant glioma cells

  1999cited by this paper
• Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb

  1999cited by this paper
• E1A can provoke G1 exit that is refractory to p21 and independent of activating cdk2.

  1999cited by this paper
• Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines.

  1999cited by this paper
• The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells

  1998cited by this paper
• Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.

  1998cited by this paper
• Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors

  1998cited by this paper
• p53-dependent cell death/apoptosis is required for a productive adenovirus infection

  1998cited by this paper
• Innate Immune Mechanisms Dominate Elimination of Adenoviral Vectors Following In Vivo Administration

  1997cited by this paper
• Tumorigenicity of cerebellar primitive neuro‐ectodermal tumors in athymic mice correlates with poor prognosis in children

  1996cited by this paper
• CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.

  1996cited by this paper

• The role of viruses in cancer development versus cancer therapy: An oncological perspective

  2023cites this paper
• Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements

  2022cites this paper
• MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy

  2021cites this paper
• Oncolytic virus therapy in cancer: A current review

  2021cites this paper
• The Effect of PEI-Mediated E1A on the Radiosensitivity of Hepatic Carcinoma Cells

  2020cites this paper
• The Oncolytic Virus in Cancer Diagnosis and Treatment

  2020cites this paper
• Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy

  2018cites this paper
• Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy

  2017cites this paper
• STRATEGIES TO ENHANCE EFFICACY OF ONCOLYTIC VIROTHERAPY

  2016cites this paper
• Modeling of Malignant Glioma and Investigations into Novel Treatments

  2015influential citation
• Targeting glioblastoma with oncolytic adenovirus delta 24

  2015cites this paper
• Sigma 1 Receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation.

  2015cites this paper
• In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells

  2015cites this paper
• An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells.

  2015influential citation
• Low pathogenic human enteroviruses as novel anti-cancer agents against malignant glioma

  2014cites this paper
• The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity

  2014cites this paper
• Cytotoxic effect of a combination of bluetongue virus and radiation on prostate cancer

  2014cites this paper
• Experimental adenovirus gene therapy for cancer patients with advanced tumors : Translational medicine from basic research to the patient's bedside

  2013cites this paper
• Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?

  2013cites this paper
• Advances in adenovirus-mediated p53 cancer gene therapy

  2013cites this paper
• A conditionally replicating adenovirus carrying interleukin‐24 sensitizes melanoma cells to radiotherapy via apoptosis

  2012cites this paper
• Improving oncolytic viral therapy for glioma

  2011cites this paper
• Oncolytic Adenoviruses with Radiation Therapy for Treatment of Prostate Cancer

  2011cites this paper
• Characterization and Development of Vesicular Stomatitis Virus For Use as an Oncolytic Vector

  2011cites this paper
• Evaluation of adenovirus capsid labeling versus transgene expression

  2010cites this paper
• Adenoviral gene therapy in high-grade malignant glioma.

  2010cites this paper
• Intelligent Design: Combination Therapy With Oncolytic Viruses.

  2010cites this paper
• Oncolytic viral therapy of malignant glioma

  2009cites this paper
• Cancer gene therapy with oncolytic adenoviruses.

  2009cites this paper
• Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect

  2009cites this paper
• Armed replicating adenoviruses for cancer virotherapy

  2009cites this paper
• Development of approaches for immunotherapy by chimeric antigen receptor modified hematopoietic stem cell transfer

  2009cites this paper
• Viruses, gene therapy and stem cells for the treatment of human glioma

  2009cites this paper
• Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

  2008cites this paper
• Oncotargets and Therapy Dovepress Clinical Utility of Recombinant Adenoviral Human P53 Gene Therapy: Current Perspectives

  year unknowncites this paper